NCCN VERSION 2 2015

161 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-86
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
randomised trial. The Lancet 2012. Available at:
.
266. Gray R, Rea D, Handley K, et al. aTTom (adjuvant Tamoxifen—To
offer more?): Randomized trial of 10 versus 5 years of adjuvant
tamoxifen among 6,934 women with estrogen receptor-positive (ER+)
or ER untested breast cancer—Preliminary results[ abstract]. J Clin
Oncol 2008;15_Suppl:Abstract 513. Available at:
.
267. Pritchard KI. Ovarian suppression/ablation in premenopausal ER-
positive breast cancer patients. Issues and recommendations. Oncology
(Williston Park) 2009;23:27-33. Available at:
.
268. Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for
premenopausal women with breast cancer. Breast 2009;18 Suppl
3:S122-130. Available at:
.
269. Tan SH, Wolff AC. The role of ovarian ablation in the adjuvant
therapy of breast cancer. Curr Oncol Rep 2008;10:27-37. Available at:
.
270. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-
hormone-releasing hormone agonists as adjuvant treatment in
premenopausal patients with hormone-receptor-positive breast cancer:
a meta-analysis of individual patient data from randomised adjuvant
trials. Lancet 2007;369:1711-1723. Available at:
.
271. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine
therapy for premenopausal women with axillary lymph node-positive,
steroid hormone receptor-positive breast cancer: results from INT 0101
(E5188). J Clin Oncol 2005;23:5973-5982. Available at:
.
272. Ejlertsen B, Mouridsen HT, Jensen MB, et al. Similar efficacy for
ovarian ablation compared with cyclophosphamide, methotrexate, and
fluorouracil: from a randomized comparison of premenopausal patients
with node-positive, hormone receptor-positive breast cancer. J Clin
Oncol 2006;24:4956-4962. Available at:
.
273. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for
adjuvant therapy of early breast cancer in premenopausal women.
Cochrane Database Syst Rev 2009:CD004562. Available at:
.
274. Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the
ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal
women with node-positive breast cancer. Eur J Cancer 2003;39:1711-
1717. Available at:
275. Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide,
methotrexate and fluorouracil (CMF) versus hormonal ablation with
leuprorelin acetate as adjuvant treatment of node-positive,
premenopausal breast cancer patients: preliminary results of the
TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin
Acetate). Anticancer Res 2002;22:2325-2332. Available at:
.
276. Thomson CS, Twelves CJ, Mallon EA, Leake RE. Adjuvant ovarian
ablation vs CMF chemotherapy in premenopausal breast cancer
patients: trial update and impact of immunohistochemical assessment of
ER status. Breast 2002;11:419-429. Available at:
.
277. von Minckwitz G, Graf E, Geberth M, et al. CMF versus goserelin
as adjuvant therapy for node-negative, hormone-receptor-positive
breast cancer in premenopausal patients: a randomised trial (GABG
trial IV-A-93). Eur J Cancer 2006;42:1780-1788. Available at:
.